Clinical TrialsThe Phase 3 EMPOWHER clinical trial of zanidatamab in combination with chemotherapy for HER2+ advanced breast cancer could open new treatment possibilities and drive investor interest.
Drug Development And ApprovalZanidatamab is showing promising potential in a variety of HER2+ cancers, with Jazz's R&D Day highlighting its significance as the most meaningful pipeline agent.
Financial OutlookWith Jazz's confidence in zanidatamab's peak revenue opportunity exceeding $2 billion, driven by multiple indications, the drug represents a substantial growth prospect for the company.